Statements of Changes in Stockholders' Equity (Deficit) (USD $)	Total USD ($)	Issuance During Period 1st Founders USD ($)	Issuance During Period 1st Cash USD ($)	Issuance During Period 1st Stock Option Exercises USD ($)	Issuance During Period 2nd Exchange for assets contributed USD ($)	Issuance During Period 2nd Cash USD ($)	Issuance During Period 2nd Stock Option Exercises USD ($)	Issuance During Period 3rd Cash USD ($)	Issuance During Period 3rd Stock Option Exercises USD ($)	Issuance During Period 4th Cash USD ($)	Issuance During Period 4th Stock Option Exercises USD ($)	Issuance During Period 5th Cash USD ($)	Issuance During Period 5th Stock Option Exercises USD ($)	Issuance During Period 5th Services USD ($)	Issuance During Period 6th Cash USD ($)	Issuance During Period 7th Cash USD ($)	Issuance During Period 7th Finder Fee USD ($)	Issuance During Period 8th Cash USD ($)	Issuance During Period 9th Cash USD ($)	Issuance During Period 10th Cash USD ($)	Issuance During Period 11th Cash USD ($)	Issuance During Period 11th Warrant, Cash Exercise USD ($)	Issuance During Period 11th Stock Option Exercises USD ($)	Issuance During Period 12th Cash USD ($)	Issuance During Period 13th Cash USD ($)	Issuance During Period 14th Cash USD ($)	Issuance During Period 15th Cash USD ($)	Issuance During Period 15th Stock Option Exercises USD ($)	Issuance During Period 16th Cash USD ($)	Issuance During Period 17th Cash USD ($)	Issuance During Period 18th Patents USD ($)	Common Stock USD ($)	Common Stock Issuance During Period 1st Founders USD ($)	Common Stock Issuance During Period 1st Cash USD ($)	Common Stock Issuance During Period 1st Stock Option Exercises USD ($)	Common Stock Issuance During Period 2nd Exchange for assets contributed USD ($)	Common Stock Issuance During Period 2nd Cash USD ($)	Common Stock Issuance During Period 2nd Stock Option Exercises	Common Stock Issuance During Period 3rd Cash USD ($)	Common Stock Issuance During Period 3rd Stock Option Exercises USD ($)	Common Stock Issuance During Period 4th Cash USD ($)	Common Stock Issuance During Period 4th Stock Option Exercises USD ($)	Common Stock Issuance During Period 5th Cash USD ($)	Common Stock Issuance During Period 5th Stock Option Exercises	Common Stock Issuance During Period 5th Services	Common Stock Issuance During Period 6th Cash USD ($)	Common Stock Issuance During Period 7th Cash USD ($)	Common Stock Issuance During Period 7th Finder Fee	Common Stock Issuance During Period 8th Cash USD ($)	Common Stock Issuance During Period 9th Cash USD ($)	Common Stock Issuance During Period 10th Cash USD ($)	Common Stock Issuance During Period 11th Cash USD ($)	Common Stock Issuance During Period 11th Warrant, Cash Exercise USD ($)	Common Stock Issuance During Period 11th Stock Option Exercises USD ($)	Common Stock Issuance During Period 12th Cash USD ($)	Common Stock Issuance During Period 13th Cash USD ($)	Common Stock Issuance During Period 14th Cash USD ($)	Common Stock Issuance During Period 15th Cash USD ($)	Common Stock Issuance During Period 15th Stock Option Exercises	Common Stock Issuance During Period 16th Cash USD ($)	Common Stock Issuance During Period 17th Cash USD ($)	Common Stock Issuance During Period 18th Patents USD ($)	Additional Paid-in Capital USD ($)	Additional Paid-in Capital Issuance During Period 1st Founders USD ($)	Additional Paid-in Capital Issuance During Period 1st Cash USD ($)	Additional Paid-in Capital Issuance During Period 1st Stock Option Exercises USD ($)	Additional Paid-in Capital Issuance During Period 2nd Cash USD ($)	Additional Paid-in Capital Issuance During Period 2nd Stock Option Exercises USD ($)	Additional Paid-in Capital Issuance During Period 3rd Cash USD ($)	Additional Paid-in Capital Issuance During Period 3rd Stock Option Exercises USD ($)	Additional Paid-in Capital Issuance During Period 4th Cash USD ($)	Additional Paid-in Capital Issuance During Period 4th Stock Option Exercises USD ($)	Additional Paid-in Capital Issuance During Period 5th Cash USD ($)	Additional Paid-in Capital Issuance During Period 5th Stock Option Exercises USD ($)	Additional Paid-in Capital Issuance During Period 5th Services USD ($)	Additional Paid-in Capital Issuance During Period 6th Cash USD ($)	Additional Paid-in Capital Issuance During Period 7th Cash USD ($)	Additional Paid-in Capital Issuance During Period 7th Finder Fee USD ($)	Additional Paid-in Capital Issuance During Period 8th Cash USD ($)	Additional Paid-in Capital Issuance During Period 9th Cash USD ($)	Additional Paid-in Capital Issuance During Period 10th Cash USD ($)	Additional Paid-in Capital Issuance During Period 11th Cash USD ($)	Additional Paid-in Capital Issuance During Period 11th Warrant, Cash Exercise USD ($)	Additional Paid-in Capital Issuance During Period 11th Stock Option Exercises USD ($)	Additional Paid-in Capital Issuance During Period 12th Cash USD ($)	Additional Paid-in Capital Issuance During Period 13th Cash USD ($)	Additional Paid-in Capital Issuance During Period 14th Cash USD ($)	Additional Paid-in Capital Issuance During Period 15th Cash USD ($)	Additional Paid-in Capital Issuance During Period 15th Stock Option Exercises USD ($)	Additional Paid-in Capital Issuance During Period 16th Cash USD ($)	Additional Paid-in Capital Issuance During Period 17th Cash USD ($)	Additional Paid-in Capital Issuance During Period 18th Patents USD ($)	Deficit Accumulated During the Development Stage USD ($)	Treasury Stock USD ($)	Subscription Receivable USD ($)	Comprehensive Loss USD ($)
Beginning Balance at Dec. 31, 2003
Issuance of common stock (in shares)																																	9,750,000			250,000			100,000		200,000		271,000			20,000	25,000		25,000	67,000
Issuance of common stock		$ 998			$ 2			$ 100,000		$ 200,000		$ 264,400			$ 18,000	$ 25,000		$ 22,500	$ 65,250														$ 98			$ 2			$ 1		$ 2		$ 3							$ 1														$ 900					$ 99,999		$ 199,998		$ 264,397			$ 18,000	$ 25,000		$ 22,500	$ 65,249
Net loss	(673,827)																																																																																												(673,827)
Ending Balance at Dec. 31, 2004	22,323																															107																															696,043																														(673,827)
Ending Balance (in shares) at Dec. 31, 2004																																10,708,000
Purchase of treasury stock (in shares)																																																																																														750,000
Purchase of treasury stock	(750)																																																																																													(750)
Issuance of common stock (in shares)																																		625,998			500,000		75,000		24,000		25,000			142,750		6,375	67,000	12,500	47,500		150,000
Issuance of common stock			614,198			500,000		145,000		47,200		45,000			283,000		(12,750)	124,500	25,000	95,000		300,000												6			5		1							2			1				1												614,192		499,995		144,999		47,200		45,000			282,998		(12,750)	124,499	25,000	95,000		299,999
Share-based compensation (Note I[2])	771,756																																																														771,756
Issuance of options in connection with a litigation settlement (Note K[5])	10,479																																																														10,479
Offering costs on private placement memorandum	(30,000)																																																														(30,000)
Net loss	(2,752,915)																																																																																												(2,752,915)
Ending Balance at Dec. 31, 2005	187,041																															123																															3,614,410																														(3,426,742)	(750)
Ending Balance (in shares) at Dec. 31, 2005																																12,384,123																																																														750,000
Purchase of treasury stock (in shares)																																																																																														10,000
Purchase of treasury stock	(20,000)																																																																																													(20,000)
Issuance of common stock (in shares)																																			134,000			10,000	30,000		47,500		500			28,500	77,467		25,500	25,000	19,500	8,333			75,666	18,365
Issuance of common stock				268,000			20,000	55,000		135,000		1,500			84,600	229,950		71,000	75,000	58,500	25,000			191,000	55,100										2												1		1						1											267,998		20,000	55,000		135,000		1,500			84,600	229,949		70,999	75,000	58,500	25,000			190,999	55,100
Share-based compensation (Note I[2])	2,152,615																																																														2,152,615
Issuance of common stock through purchase of treasury stock ($2.00 per share) in January 2006 (in shares)																																																																																														(10,000)
Issuance of common stock through purchase of treasury stock ($2.00 per share) in January 2006	20,000																																																																																													20,000
Net increase (decrease) in subscription receivable	(36,100)																																																																																														(36,100)
Net loss	(4,226,169)																																																																																												(4,226,169)
Ending Balance at Dec. 31, 2006	(652,963)																															128																															7,036,670																														(7,652,911)	(750)	(36,100)
Ending Balance (in shares) at Dec. 31, 2006																																12,884,454																																																														750,000
Issuance of common stock (in shares)																																		200,000			2,500		373,764		372,498		33,125			227,096	106,750		38,500	51,250	213,250	167,000			159,575	264,300	25,000		13,200
Issuance of common stock			180,000			7,500		1,070,250		1,066,232		132,500			780,914	402,500		154,000	186,700	776,400	622,700			551,170	1,025,980	50,000		3,300						2					4		4					2	1			1	2	2			2	3									179,998		7,500		1,070,246		1,066,228		132,500			780,912	402,499		154,000	186,699	776,398	622,698			551,168	1,025,977	50,000		3,300
Share-based compensation (Note I[2])	5,608,902																																																														5,608,902
Offering costs on private placement memorandum	(30,000)																																																														(30,000)
Net increase (decrease) in subscription receivable	(201,900)																																																																																														(201,900)
Net loss	(8,391,250)																																																																																												(8,391,250)
Ending Balance at Dec. 31, 2007	3,342,935																															151																															19,625,695																														(16,044,161)	(750)	(238,000)
Ending Balance (in shares) at Dec. 31, 2007																																15,132,262																																																														750,000
Issuance of warrants for acquisition of patents in December 2008	3,375,286																																																														3,375,286
Issuance of common stock (in shares)																																			1,069,000		343,950			390,000	74,950			21,000		63,750	265,000		394,375	36,250	10,000	4,250			73,500	45,000	86,100	306,100		180,000	270,750	1,000,000
Issuance of common stock				267,250		1,302,300			97,500	284,320			5,250		237,900	964,500		1,455,130	133,000	50,000	17,000			342,000	213,800	402,140	1,518,950		859,200	1,286,630	5,000,000				11		3			4	1					1	3		4						1		1	3		2	2	10				267,239	1,302,297			97,496	284,319			5,250		237,899	964,497		1,455,126	133,000	50,000	17,000			341,999	213,800	402,139	1,518,947		859,198	1,286,628	4,999,990
Share-based compensation (Note I[2])	8,730,433																																																														8,730,433
Offering costs on private placement memorandum	(45,000)																																																														(45,000)
Net increase (decrease) in subscription receivable	(21,000)																																																																																														(21,000)
Net loss	(25,781,602)																																																																																												(25,781,602)
Ending Balance at Dec. 31, 2008	4,037,922																															197																															46,123,238																														(41,825,763)	(750)	(259,000)
Beginning Balance (in shares) at Dec. 31, 2008																																19,766,237																																																														750,000
Purchase of treasury stock (in shares)																																																																																														500,000
Purchase of treasury stock	(175,000)																																																																																													(175,000)
Issuance of common stock (in shares)																																		241,200			205,200		311,980		302,400		3,125			80,972	49,333		210,120	636,977	267,026	340,368			245,705	304,777
Issuance of common stock			1,157,700			988,480		1,417,110		1,333,709		12,500			389,335	338,325		1,508,400	4,385,207	1,672,736	2,394,340			1,695,886	2,107,823									3			2		3		3					1			2	6	3	3			3	3									1,157,697		988,478		1,417,107		1,333,706		12,500			389,334	338,325		1,508,398	4,385,201	1,672,733	2,394,337			1,695,883	2,107,820
Retirement of treasury stock (in shares)																																(1,250,000)																																																														(1,250,000)
Retirement of treasury stock																																(12)																															(175,738)																															175,750
Share-based compensation (Note I[2])	26,520,511																																																														26,520,511
Offering costs on private placement memorandum	(105,000)																																																														(105,000)
Net increase (decrease) in subscription receivable	154,381																																																																																														154,381
Net loss	(35,558,538)																																																																																												(35,558,538)
Ending Balance at Dec. 31, 2009	14,275,827																															217																															91,764,530																														(77,384,301)		(104,619)
Ending Balance (in shares) at Dec. 31, 2009																																21,715,420
Issuance of common stock (in shares)																																		16,000			18,000		25,500		21,000		65,800			316,080	42,600		6,000	19,098	290,220			64,100
Issuance of common stock			183,000			212,250		307,594		250,812		761,087			3,614,140	489,955		75,000	229,163	3,368,054			128,200																1				1			3					3			1											183,000		212,250		307,593		250,812		761,086			3,614,137	489,955		75,000	229,163	3,368,051			128,199
Share-based compensation (Note I[2])	6,523,056																																																														6,523,056
Net increase (decrease) in subscription receivable	(45,381)																																																																																														(45,381)
Net loss	(19,051,455)																																																																																												(19,051,455)
Ending Balance at Dec. 31, 2010	11,321,302																															226																															107,906,832																														(96,435,756)		(150,000)
Ending Balance (in shares) at Dec. 31, 2010																																22,599,818
Issuance of common stock (in shares)																																		106,367			51,600		70,134			92,500			4,000
Issuance of common stock			1,229,323			594,850		839,262			92,500			50,000																				1					1			1																							1,229,322		594,850		839,261			92,499			50,000
Share-based compensation (Note I[2])	8,772,753																																																														8,772,753
Net increase (decrease) in subscription receivable	150,000																																																																																														150,000
Net loss	(19,049,760)																																																																																												(19,049,760)
Comprehensive loss																																																																																																(19,049,760)
Ending Balance at Dec. 31, 2011	$ 4,000,230																															$ 229																															$ 119,485,517																														$ (115,485,516)
Ending Balance (in shares) at Dec. 31, 2011																																22,924,419

Neogenix Oncology Inc 10-K